Corbevax疫苗於印度等通過EUA

2022/05/14

德州兒童醫院與印度Biological E’s公司合作開發的次單位蛋白疫苗Corbevax（S1-RBD/CpG1018)，Phase3 臨床試驗也是跟Covishield (印度AZ)作免疫橋接驗証：

CORBEVAX vs COVISHIELD 中和抗體GMTR :1.15

Corbevax 在印度（五歲以上可以接種）及非洲的波茲瓦納取得 EUA

外文報導

其它相關訊息：

wiki Corbevax：

… A phase I clinical trial was carried out to evaluate the safety and immunogenicity of the vaccine candidate in about 360 participants.[4] The phase II concluded in April 2021.[10][11][12]

In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study.[13][11] As of December 2021, Biological E announced positive results, but some experts criticized the lack of public data from phase III trials.[14] The developer specifically claimed the vaccine appeared to be over 90% effective against the original variant based on antibody levels.